{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:40Z","timestamp":1740107440561,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Emmert Hobbs Foundation Endowment"},{"name":"Maryland Technology Development Corporation","award":["Project 1120-005"],"award-info":[{"award-number":["Project 1120-005"]}]},{"DOI":"10.13039\/100004972","name":"Maryland Industrial Partnerships","doi-asserted-by":"publisher","award":["Project 6502"],"award-info":[{"award-number":["Project 6502"]}],"id":[{"id":"10.13039\/100004972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM066691","P30CA006973","UL1TR003098","S10RR026824"],"award-info":[{"award-number":["T32GM066691","P30CA006973","UL1TR003098","S10RR026824"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00280-023-04539-2","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T08:02:31Z","timestamp":1685433751000},"page":"39-50","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ART714 is a best-in-class antileukemic 2-carbon-linked dimeric artemisinin derivative"],"prefix":"10.1007","volume":"92","author":[{"given":"Amanda B.","family":"Kagan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blake S.","family":"Moses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rena","family":"Lapidus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan T.","family":"Mott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesha","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole M.","family":"Anders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen W.","family":"Hoag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5739-6868","authenticated-orcid":false,"given":"Michelle A.","family":"Rudek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curt I.","family":"Civin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"issue":"12","key":"4539_CR1","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/cncr.33458","volume":"127","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, Jabbour E, Kantarjian HM (2021) De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer 127(12):2049\u20132061. https:\/\/doi.org\/10.1002\/cncr.33458","journal-title":"Cancer"},{"issue":"15","key":"4539_CR2","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S, Chyla B, Popovic R, Salem AH, Agarwal S, Xu T, Fakouhi KM, Humerickhouse R, Hong WJ, Hayslip J, Roboz GJ (2019) Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol 37(15):1277\u20131284. https:\/\/doi.org\/10.1200\/JCO.18.01600","journal-title":"J Clin Oncol"},{"issue":"1","key":"4539_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752","journal-title":"Blood"},{"issue":"4","key":"4539_CR4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, Krug A, Jones CL, Adane B, Khan N, Ponder J, Schowinsky J, Abbott D, Hammes A, Myers JR, Ashton JM, Nemkov T, D\u2019Alessandro A, Gutman JA, Ramsey HE, Savona MR, Smith CA, Jordan CT (2020) Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov 10(4):536\u2013551. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0710","journal-title":"Cancer Discov"},{"issue":"11","key":"4539_CR5","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R, Pomilio G, Ivey A, Salmon JM, Glytsou C, Fleming SA, Zhang Q, Ma H, Patel KP, Kornblau SM, Xu Z, Chua CC, Chen X, Blombery P, Flensburg C, Cummings N, Aifantis I, Kantarjian H, Huang DCS, Roberts AW, Majewski IJ, Konopleva M, Wei AH (2020) Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135(11):791\u2013803. https:\/\/doi.org\/10.1182\/blood.2019003988","journal-title":"Blood"},{"key":"4539_CR6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014241","author":"M Janssen","year":"2022","unstructured":"Janssen M, Schmidt C, Bruch PM, Blank MF, Rohde C, Waclawiczek A, Heid D, Renders S, Gollner S, Vierbaum L, Besenbeck B, Herbst SA, Knoll M, Kolb C, Przybylla A, Weidenauer K, Ludwig AK, Fabre MA, Gu M, Schlenk RF, Stolzel F, Bornhauser M, Rollig C, Platzbecker U, Baldus CD, Serve H, Sauer T, Raffel S, Pabst C, Vassiliou GS, Vick B, Jeremias I, Trumpp A, Krijgsveld J, Muller-Tidow C, Dietrich S (2022) Venetoclax synergizes with Gilteritinib in FLT3 wildtype high-risk acute myeloid leukemia by suppressing MCL-1. Blood. https:\/\/doi.org\/10.1182\/blood.2021014241","journal-title":"Blood"},{"issue":"2","key":"4539_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/MOH.0000000000000698","volume":"29","author":"S Shimony","year":"2022","unstructured":"Shimony S, Stone RM, Stahl M (2022) Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes. Curr Opin Hematol 29(2):63\u201373. https:\/\/doi.org\/10.1097\/MOH.0000000000000698","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"4539_CR8","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","volume":"6","author":"R Zhu","year":"2021","unstructured":"Zhu R, Li L, Nguyen B, Seo J, Wu M, Seale T, Levis M, Duffield A, Hu Y, Small D (2021) FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation. Signal Transduct Target Ther 6(1):186. https:\/\/doi.org\/10.1038\/s41392-021-00578-4","journal-title":"Signal Transduct Target Ther"},{"issue":"22","key":"4539_CR9","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","volume":"25","author":"J Ma","year":"2019","unstructured":"Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Wang G, Zhao L, Lin H, Wang Y, Taub JW, Ge Y (2019) Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia. Clin Cancer Res 25(22):6815\u20136826. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0832","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4539_CR10","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","volume":"106","author":"R Singh Mali","year":"2021","unstructured":"Singh Mali R, Zhang Q, DeFilippis RA, Cavazos A, Kuruvilla VM, Raman J, Mody V, Choo EF, Dail M, Shah NP, Konopleva M, Sampath D, Lasater EA (2021) Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD + acute myeloid leukemia models. Haematologica 106(4):1034\u20131046. https:\/\/doi.org\/10.3324\/haematol.2019.244020","journal-title":"Haematologica"},{"issue":"1","key":"4539_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13045-020-00973-4","volume":"13","author":"LT Brinton","year":"2020","unstructured":"Brinton LT, Zhang P, Williams K, Canfield D, Orwick S, Sher S, Wasmuth R, Beaver L, Cempre C, Skinner J, Cannon M, Govande M, Harrington B, Lehman A, Byrd JC, Lapalombella R, Blachly JS (2020) Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia. J Hematol Oncol 13(1):139. https:\/\/doi.org\/10.1186\/s13045-020-00973-4","journal-title":"J Hematol Oncol"},{"issue":"2","key":"4539_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","volume":"11","author":"A Maiti","year":"2021","unstructured":"Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY (2021) Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25. https:\/\/doi.org\/10.1038\/s41408-021-00410-w","journal-title":"Blood Cancer J"},{"issue":"5","key":"4539_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41408-022-00670-0","volume":"12","author":"M Yilmaz","year":"2022","unstructured":"Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N (2022) Hypomethylating agent and venetoclax with FLT3 inhibitor \u201ctriplet\u201d therapy in older\/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77. https:\/\/doi.org\/10.1038\/s41408-022-00670-0","journal-title":"Blood Cancer J"},{"issue":"2","key":"4539_CR14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/bjh.17746","volume":"196","author":"S Kayser","year":"2022","unstructured":"Kayser S, Levis MJ (2022) Updates on targeted therapies for acute myeloid leukaemia. Br J Haematol 196(2):316\u2013328. https:\/\/doi.org\/10.1111\/bjh.17746","journal-title":"Br J Haematol"},{"issue":"6","key":"4539_CR15","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1080\/10428194.2020.1864358","volume":"62","author":"D Abbott","year":"2021","unstructured":"Abbott D, Cherry E, Amaya M, McMahon C, Schwartz M, Winters A, Schowinsky J, Jordan CT, Smith C, Gutman JA, Pollyea DA (2021) The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia. Leuk Lymphoma 62(6):1466\u20131473. https:\/\/doi.org\/10.1080\/10428194.2020.1864358","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"4539_CR16","doi-asserted-by":"publisher","first-page":"7558","DOI":"10.1158\/1078-0432.CCR-17-1231","volume":"23","author":"A Budhraja","year":"2017","unstructured":"Budhraja A, Turnis ME, Churchman ML, Kothari A, Yang X, Xu H, Kaminska E, Panetta JC, Finkelstein D, Mullighan CG, Opferman JT (2017) Modulation of navitoclax sensitivity by dihydroartemisinin-mediated MCL-1 repression in BCR-ABL(+) B-lineage acute lymphoblastic leukemia. Clin Cancer Res 23(24):7558\u20137568. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1231","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4539_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/bcmd.2002.0530","volume":"29","author":"T Efferth","year":"2002","unstructured":"Efferth T, Verdorfer I, Miyachi H, Sauerbrey A, Drexler HG, Chitambar CR, Haber M, Gebhart E (2002) Genomic imbalances in drug-resistant T-cell acute lymphoblastic CEM leukemia cell lines. Blood Cells Mol Dis 29(1):1\u201313. https:\/\/doi.org\/10.1006\/bcmd.2002.0530","journal-title":"Blood Cells Mol Dis"},{"issue":"6","key":"4539_CR18","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s00280-016-3038-2","volume":"77","author":"CD Drenberg","year":"2016","unstructured":"Drenberg CD, Buaboonnam J, Orwick SJ, Hu S, Li L, Fan Y, Shelat AA, Guy RK, Rubnitz J, Baker SD (2016) Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer Chemother Pharmacol 77(6):1231\u20131243. https:\/\/doi.org\/10.1007\/s00280-016-3038-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"4539_CR19","doi-asserted-by":"publisher","first-page":"7268","DOI":"10.18632\/oncotarget.6896","volume":"7","author":"JM Fox","year":"2016","unstructured":"Fox JM, Moynihan JR, Mott BT, Mazzone JR, Anders NM, Brown PA, Rudek MA, Liu JO, Arav-Boger R, Posner GH, Civin CI, Chen X (2016) Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs. Oncotarget 7(6):7268\u20137279. https:\/\/doi.org\/10.18632\/oncotarget.6896","journal-title":"Oncotarget"},{"issue":"3","key":"4539_CR20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/bloodadvances.2020003429","volume":"5","author":"BS Moses","year":"2021","unstructured":"Moses BS, McCullough S, Fox JM, Mott BT, Bentzen SM, Kim M, Tyner JW, Lapidus RG, Emadi A, Rudek MA, Kingsbury TJ, Civin CI (2021) Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax. Blood Adv 5(3):711\u2013724. https:\/\/doi.org\/10.1182\/bloodadvances.2020003429","journal-title":"Blood Adv"},{"key":"4539_CR21","doi-asserted-by":"publisher","first-page":"790037","DOI":"10.3389\/fonc.2021.790037","volume":"11","author":"AB Kagan","year":"2021","unstructured":"Kagan AB, Moses BS, Mott BT, Rai G, Anders NM, Rudek MA, Civin CI (2021) A novel 2-carbon-linked dimeric artemisinin with potent antileukemic activity and favorable pharmacology. Front Oncol 11:790037. https:\/\/doi.org\/10.3389\/fonc.2021.790037","journal-title":"Front Oncol"},{"issue":"6","key":"4539_CR22","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1021\/jm400058j","volume":"56","author":"BT Mott","year":"2013","unstructured":"Mott BT, Tripathi A, Siegler MA, Moore CD, Sullivan DJ, Posner GH (2013) Synthesis and antimalarial efficacy of two-carbon-linked, artemisinin-derived trioxane dimers in combination with known antimalarial drugs. J Med Chem 56(6):2630\u20132641. https:\/\/doi.org\/10.1021\/jm400058j","journal-title":"J Med Chem"},{"issue":"3","key":"4539_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF01062139","volume":"16","author":"AJ Bailer","year":"1988","unstructured":"Bailer AJ (1988) Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16(3):303\u2013309. https:\/\/doi.org\/10.1007\/BF01062139","journal-title":"J Pharmacokinet Biopharm"},{"issue":"7","key":"4539_CR24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/jps.2600820718","volume":"82","author":"J Yuan","year":"1993","unstructured":"Yuan J (1993) Estimation of variance for AUC in animal studies. J Pharm Sci 82(7):761\u2013763","journal-title":"J Pharm Sci"},{"issue":"6","key":"4539_CR25","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41565-019-0406-1","volume":"14","author":"V Trujillo-Alonso","year":"2019","unstructured":"Trujillo-Alonso V, Pratt EC, Zong H, Lara-Martinez A, Kaittanis C, Rabie MO, Longo V, Becker MW, Roboz GJ, Grimm J, Guzman ML (2019) FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels. Nat Nanotechnol 14(6):616\u2013622. https:\/\/doi.org\/10.1038\/s41565-019-0406-1","journal-title":"Nat Nanotechnol"},{"issue":"4","key":"4539_CR26","doi-asserted-by":"publisher","first-page":"e1054549","DOI":"10.1080\/23723556.2015.1054549","volume":"2","author":"Y Yu","year":"2015","unstructured":"Yu Y, Xie Y, Cao L, Yang L, Yang M, Lotze MT, Zeh HJ, Kang R, Tang D (2015) The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol Cell Oncol 2(4):e1054549. https:\/\/doi.org\/10.1080\/23723556.2015.1054549","journal-title":"Mol Cell Oncol"},{"key":"4539_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bcp.2017.06.112","volume":"140","author":"L Probst","year":"2017","unstructured":"Probst L, Dachert J, Schenk B, Fulda S (2017) Lipoxygenase inhibitors protect acute lymphoblastic leukemia cells from ferroptotic cell death. Biochem Pharmacol 140:41\u201352. https:\/\/doi.org\/10.1016\/j.bcp.2017.06.112","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"4539_CR28","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3892\/ijo.2020.5116","volume":"57","author":"I Kato","year":"2020","unstructured":"Kato I, Kasukabe T, Kumakura S (2020) MeninMLL inhibitors induce ferroptosis and enhance the antiproliferative activity of auranofin in several types of cancer cells. Int J Oncol 57(4):1057\u20131071. https:\/\/doi.org\/10.3892\/ijo.2020.5116","journal-title":"Int J Oncol"},{"issue":"5","key":"4539_CR29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D (2021) Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol 18(5):280\u2013296. https:\/\/doi.org\/10.1038\/s41571-020-00462-0","journal-title":"Nat Rev Clin Oncol"},{"key":"4539_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186751","author":"LR Thompson","year":"2020","unstructured":"Thompson LR, Oliveira TG, Hermann ER, Chowanadisai W, Clarke SL, Montgomery MR (2020) Distinct TP53 mutation types exhibit increased sensitivity to ferroptosis independently of changes in iron regulatory protein activity. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21186751","journal-title":"Int J Mol Sci"},{"issue":"7545","key":"4539_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14344","volume":"520","author":"L Jiang","year":"2015","unstructured":"Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, Baer R, Gu W (2015) Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520(7545):57\u201362. https:\/\/doi.org\/10.1038\/nature14344","journal-title":"Nature"},{"key":"4539_CR32","doi-asserted-by":"publisher","first-page":"172953","DOI":"10.1016\/j.ejphar.2020.172953","volume":"872","author":"C Ishikawa","year":"2020","unstructured":"Ishikawa C, Senba M, Mori N (2020) Evaluation of artesunate for the treatment of adult T-cell leukemia\/lymphoma. Eur J Pharmacol 872:172953. https:\/\/doi.org\/10.1016\/j.ejphar.2020.172953","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"4539_CR33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1089\/dna.2021.1145","volume":"41","author":"X Zhang","year":"2022","unstructured":"Zhang X, Ai Z, Zhang Z, Dong R, Wang L, Jin S, Wei H (2022) Dihydroartemisinin triggers ferroptosis in multidrug-resistant leukemia cells. DNA Cell Biol 41(8):705\u2013715. https:\/\/doi.org\/10.1089\/dna.2021.1145","journal-title":"DNA Cell Biol"},{"key":"4539_CR34","doi-asserted-by":"publisher","first-page":"175028","DOI":"10.1016\/j.ejphar.2022.175028","volume":"926","author":"H Zhang","year":"2022","unstructured":"Zhang H, Zhuo Y, Li D, Zhang L, Gao Q, Yang L, Yuan X (2022) Dihydroartemisinin inhibits the growth of pancreatic cells by inducing ferroptosis and activating antitumor immunity. Eur J Pharmacol 926:175028. https:\/\/doi.org\/10.1016\/j.ejphar.2022.175028","journal-title":"Eur J Pharmacol"},{"key":"4539_CR35","doi-asserted-by":"publisher","first-page":"112742","DOI":"10.1016\/j.biopha.2022.112742","volume":"148","author":"S Li","year":"2022","unstructured":"Li S, Xu W, Wang H, Tang T, Ma J, Cui Z, Shi H, Qin T, Zhou H, Li L, Jiang T, Li C (2022) Ferroptosis plays an essential role in the antimalarial mechanism of low-dose dihydroartemisinin. Biomed Pharmacother 148:112742. https:\/\/doi.org\/10.1016\/j.biopha.2022.112742","journal-title":"Biomed Pharmacother"},{"key":"4539_CR36","doi-asserted-by":"publisher","first-page":"14797","DOI":"10.1016\/j.ejphar.2022.174797","volume":"919","author":"N Han","year":"2022","unstructured":"Han N, Li LG, Peng XC, Ma QL, Yang ZY, Wang XY, Li J, Li QR, Yu TT, Xu HZ, Xu X, Chen X, Wang MF, Li TF (2022) Ferroptosis triggered by dihydroartemisinin facilitates chlorin e6 induced photodynamic therapy against lung cancerthrough inhibiting GPX4 and enhancing ROS. Eur J Pharmacol 919:14797. https:\/\/doi.org\/10.1016\/j.ejphar.2022.174797","journal-title":"Eur J Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04539-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04539-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04539-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T11:05:16Z","timestamp":1686567916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04539-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4539"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04539-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"24 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"B.T.M. is an inventor on patent\/patent applications related to the 2C-ARTs synthesis (US20150361088A1, expiration 01\/22\/2034). M.A.R. and C.I.C. are inventors on patent\/patent applications related to the Treatment of Leukemia with Artemisinin Derivatives and Combinations with Other Antineoplastic Agents (US Patent Application No. 14\/757, 433\/US Patent 9,918,972\/expiration 12\/23\/35). B.T.M., C.I.C., and M.A.R. are founders of Geminus Therapeutics LLC, serve on its Board of Directors and hold equity. Funding for the study described in this publication was provided by Geminus Therapeutics LLC. Under a license agreement between Geminus Therapeutics LLC and the Johns Hopkins University, Dr. Rudek and Johns Hopkins University are entitled to royalty distributions related to technology described in the study discussed in this publication. This arrangement has been reviewed and approved by the Johns Hopkins University (M.A.R.) or University of Maryland (C.I.C.) in accordance with their conflict of interest policies. All other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}